Company News
07 May 2025
Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results. The presentation covers recent achievements including an update on the FebriDx CLIA Waiver study, strategic partnership agreements, and key priorities for the next quarter.
Take a look:
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
1 min read
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
COMPANY NEWS
2 min read
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
COMPANY NEWS
1 min read
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...